PL2247291T3 - Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit - Google Patents
Sposoby i kompozycje do leczenia nieswoistego zapalenia jelitInfo
- Publication number
- PL2247291T3 PL2247291T3 PL09708397T PL09708397T PL2247291T3 PL 2247291 T3 PL2247291 T3 PL 2247291T3 PL 09708397 T PL09708397 T PL 09708397T PL 09708397 T PL09708397 T PL 09708397T PL 2247291 T3 PL2247291 T3 PL 2247291T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- inflammatory bowel
- bowel disease
- treating inflammatory
- Prior art date
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6514408P | 2008-02-08 | 2008-02-08 | |
| EP09708397.6A EP2247291B1 (en) | 2008-02-08 | 2009-02-05 | Methods and compositions for treating inflammatory bowel disease |
| PCT/AU2009/000129 WO2009097651A1 (en) | 2008-02-08 | 2009-02-05 | Methods and compositions for treating inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2247291T3 true PL2247291T3 (pl) | 2019-05-31 |
Family
ID=40951740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09708397T PL2247291T3 (pl) | 2008-02-08 | 2009-02-05 | Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit |
Country Status (18)
| Country | Link |
|---|---|
| US (10) | US8343511B2 (pl) |
| EP (2) | EP3391882A1 (pl) |
| JP (1) | JP5572872B2 (pl) |
| AU (1) | AU2009212097B2 (pl) |
| CA (1) | CA2714043C (pl) |
| CY (1) | CY1121465T1 (pl) |
| DK (1) | DK2247291T3 (pl) |
| ES (1) | ES2708087T3 (pl) |
| HR (1) | HRP20190045T1 (pl) |
| HU (1) | HUE041305T2 (pl) |
| IL (1) | IL207420A (pl) |
| NZ (1) | NZ587250A (pl) |
| PL (1) | PL2247291T3 (pl) |
| PT (1) | PT2247291T (pl) |
| SI (1) | SI2247291T1 (pl) |
| TR (1) | TR201819940T4 (pl) |
| WO (1) | WO2009097651A1 (pl) |
| ZA (1) | ZA201005735B (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3391882A1 (en) | 2008-02-08 | 2018-10-24 | Red Hill Biopharma Ltd. | Compositions comprising rifabutin, clarithromycin, and clofazimine |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| EP2890374B1 (en) | 2012-08-30 | 2019-04-03 | The Texas A&M University System | Compositions and methods for drug-sensitization or inhibition of a cancer cell |
| WO2015123392A1 (en) * | 2014-02-14 | 2015-08-20 | The Texas A&M University System | Compositions and methods for inhibition of angiogenesis and lymphangiogenesis |
| CN106535941A (zh) * | 2014-05-22 | 2017-03-22 | 约翰·托德·金斯特纳 | 使用紫外线血液辐照和抗生素的组合治疗疾病 |
| EP3291798A4 (en) * | 2015-05-04 | 2019-01-16 | Gufic Biosciences Limited | LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF |
| EP3359255B1 (en) | 2015-10-06 | 2025-12-24 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| CN107202848B (zh) * | 2017-07-24 | 2022-11-15 | 浙江华海药业股份有限公司 | 一种氯法齐明的液相色谱分析方法 |
| US11321665B2 (en) * | 2017-08-29 | 2022-05-03 | Weightrx Inc. | System and method of automated tracking of consumable products |
| MX2022003077A (es) * | 2019-09-12 | 2022-07-11 | BioVersys AG | Terapias de combinacion de antibioticos. |
| CA3187031A1 (en) | 2020-06-30 | 2022-01-06 | Redhill Biopharma Ltd. | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections |
| WO2022204375A1 (en) * | 2021-03-25 | 2022-09-29 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840733A (en) | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
| NZ500696A (en) * | 1997-04-01 | 2002-05-31 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease comprising mycobacterial agents, including macrolides |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| EP3391882A1 (en) | 2008-02-08 | 2018-10-24 | Red Hill Biopharma Ltd. | Compositions comprising rifabutin, clarithromycin, and clofazimine |
-
2009
- 2009-02-05 EP EP18171416.3A patent/EP3391882A1/en not_active Withdrawn
- 2009-02-05 EP EP09708397.6A patent/EP2247291B1/en active Active
- 2009-02-05 DK DK09708397.6T patent/DK2247291T3/en active
- 2009-02-05 TR TR2018/19940T patent/TR201819940T4/tr unknown
- 2009-02-05 WO PCT/AU2009/000129 patent/WO2009097651A1/en not_active Ceased
- 2009-02-05 US US12/918,310 patent/US8343511B2/en active Active
- 2009-02-05 HR HRP20190045TT patent/HRP20190045T1/hr unknown
- 2009-02-05 PL PL09708397T patent/PL2247291T3/pl unknown
- 2009-02-05 SI SI200931923T patent/SI2247291T1/sl unknown
- 2009-02-05 NZ NZ587250A patent/NZ587250A/en unknown
- 2009-02-05 HU HUE09708397A patent/HUE041305T2/hu unknown
- 2009-02-05 JP JP2010545328A patent/JP5572872B2/ja active Active
- 2009-02-05 AU AU2009212097A patent/AU2009212097B2/en active Active
- 2009-02-05 ES ES09708397T patent/ES2708087T3/es active Active
- 2009-02-05 PT PT09708397T patent/PT2247291T/pt unknown
- 2009-02-05 CA CA2714043A patent/CA2714043C/en active Active
-
2010
- 2010-08-04 IL IL207420A patent/IL207420A/en active IP Right Grant
- 2010-08-11 ZA ZA2010/05735A patent/ZA201005735B/en unknown
-
2012
- 2012-12-20 US US13/722,395 patent/US9072763B2/en active Active
-
2014
- 2014-05-07 US US14/271,814 patent/US9314477B2/en active Active
- 2014-05-07 US US14/271,758 patent/US9198926B2/en active Active
-
2016
- 2016-04-18 US US15/131,533 patent/US20160228464A1/en not_active Abandoned
-
2017
- 2017-05-03 US US15/585,879 patent/US10105379B2/en active Active
-
2018
- 2018-01-02 US US15/860,298 patent/US10143702B2/en active Active
- 2018-10-29 US US16/173,530 patent/US10434114B2/en active Active
- 2018-12-28 CY CY20181101409T patent/CY1121465T1/el unknown
-
2019
- 2019-08-28 US US16/554,201 patent/US10765691B2/en active Active
-
2020
- 2020-03-12 US US16/816,759 patent/US11090326B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL207420A0 (en) | Methods and compositions for treating inflammatory bowel disease | |
| PT2252148T (pt) | Métodos de tratamento da síndrome do intestino irritável | |
| GB2512153B (en) | Methods and compositions of molecular profiling for disease diagnostics | |
| IL195001A0 (en) | Method and means for treating inflammatory bowel disease | |
| PT2789684T (pt) | Métodos e composições para facilitar a regeneração | |
| EP2309858A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| SI2173379T1 (sl) | Sestavki in postopki za zdravljenje in diagnosticiranje raka | |
| PT2818184T (pt) | Composições e métodos para o tratamento de púrpura | |
| EP2285347A4 (en) | COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM | |
| LT2289518T (lt) | Terapinis agentas nuo uždegiminės žarnų ligos | |
| EP2125887A4 (en) | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| IL210097A0 (en) | Compositions and methods for treating unfluenza | |
| ZA201104062B (en) | Compositions and methods for controlling disease in animals | |
| EP2411006A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS | |
| ZA201000983B (en) | Methods and compositions for diagnosing disease | |
| BRPI1007600A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| EP2155249A4 (en) | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| ZA201203002B (en) | Compositions and methods for treating inflammatory disorders | |
| IL210840A0 (en) | Methods and compositions for treating and preventing autoimmune diseases | |
| PT2341937E (pt) | Composição para tratamento de doença | |
| IL196638A0 (en) | Methods and compositions for treating disease | |
| EP2140261A4 (en) | METHODS AND AGENTS FOR ASSESSING INFLAMMATORY ABDOMINAL INFECTION AND TARGETS FOR TREATMENT | |
| IL210933A0 (en) | Compositions and methods for treating inflammatory disorders | |
| SI2341937T1 (sl) | Sestavek za zdravljenje bolezni | |
| GB0707235D0 (en) | Methods and compositions for tissue regeneration |